This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Daniel A. Goldstein, MD
Departments of Clinical Pharmacology and Pediatrics

Joe T. R. Clarke, MD, PhD
Departments of Neurology and Pediatrics

Steven J. Soldin, PhD
Department of Clinical Chemistry The Hospital for Sick Children 555 University Ave Toronto, Ontario, Canada M5G 1X8

Arch Neurol. 1987;44(6):577-578.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.

—Anticonvulsant therapy is often required in children with a variety of lysosomal storage disorders. As a part of our therapeutic drug monitoring service, we have been asked to see a number of children with storage disorders in whom therapeutic phenytoin levels were difficult to achieve. Available clinical data have not been adequate to distinguish increased volume of distribution, rapid excretion, or a combination of these factors as an explanation of diminished levels. Although rapid metabolism of phenytoin is common in the pediatric age group,¹ one could postulate that lipophilic drugs might have an increased volume of distribution in these patients because of the large amounts of stored lipid material and/ or lysosomal membrane material. A larger volume of distribution would require substantially larger loading doses to achieve a given serum concentration of the drug, although ultimate steady-state concentrations would be unaffected. We have performed a formal pharmacokinetic study . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?